- Q2 2023 Biovica International AB Earnings Call TranscriptDec 15, 2022kr8.29 (-2.01%)Earnings
- Biovica International AB Market update FDA clearance TranscriptAug 18, 2022
- Q4 2022 Biovica International AB Earnings Call TranscriptJun 16, 2022kr34.38 (-3.74%)Earnings
- Biovica International AB Corporate Analyst Meeting TranscriptMay 17, 2022
- Q3 2022 Biovica International AB Earnings Call TranscriptMar 15, 2022kr27.85 (+4.84%)Earnings
- Q2 2022 Biovica International AB Earnings Call TranscriptDec 01, 2021kr38 (-5.19%)Earnings
- Q1 2022 Biovica International AB Earnings Call TranscriptSep 02, 2021kr58.28 (-0.17%)Earnings
- Biovica International AB CEO's Presentation Annual General Meeting 2021 - Pre-Recorded TranscriptAug 27, 2021
- Q4 2021 Biovica International AB Earnings Call TranscriptJun 18, 2021kr45.71 (-3.14%)Earnings
- Biovica International AB Capital Markets Day (Virtual) TranscriptJun 09, 2021
- Q3 2021 Biovica International AB Earnings Call TranscriptMar 18, 2021kr41.36 (+6.36%)Earnings
- Q2 2021 Biovica International AB Earnings Call TranscriptDec 08, 2020kr45.42 (+0.22%)Earnings
Q3 2021 Biovica International AB Earnings Call Transcript
()-&
Welcome, everyone, to our interim report presentation. So if we go to the next slide, you'll see that it will be me and Cecilia Driving, our CFO, that will perform the presentation.
And if we to the next slide after that, you'll see the agenda. So we'll start with -- or I will start with a short introduction of Biovica. We will go through the highlights for the third quarter in our fiscal year, which we're now presenting. Cecilia will walk through the financial and we will end with a summary and a Q&A where you will be able to ask us questions. And we also have had questions coming by mail before that I will start with. So that's the agenda for today.
So if we move on to the next slide, just a very short background about the company, what we do. So Biovica develops and commercializes blood-based biomarker assays with the purpose to improve monitoring of modern cancer therapies, and I'll get that a little bit to how we do that. We do that through our assay, biomarker
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)